Skip to main content
main-content

23.01.2018 | Retinal Disorders | Ausgabe 3/2018

Graefe's Archive for Clinical and Experimental Ophthalmology 3/2018

Antiplatelet and anticoagulant agents in vitreoretinal surgery: a prospective multicenter study involving 804 patients

Zeitschrift:
Graefe's Archive for Clinical and Experimental Ophthalmology > Ausgabe 3/2018
Autoren:
Cyril Meillon, Pierre Henry Gabrielle, Maxime Luu, Ludwig S. Aho-Glele, Alain M. Bron, Catherine Creuzot-Garcher, for the CFSR research net

Abstract

Purpose

To assess the rate of hemorrhagic complications after vitreoretinal surgery and the influence of antithrombotic agents.

Methods

Hemorrhagic complications of vitreoretinal procedures performed in seven ophthalmologic centers on patients treated or not treated with antiplatelet (AP) or anticoagulant (AC) agents were prospectively collected. Patients’ characteristics, surgical techniques, and complications were recorded during surgery and for 1 month after.

Results

Eight hundred four procedures were performed between January 2015 and April 2015. Among them, 18.4% were treated with AP agents (n = 148) and 7.8% with AC agents (n = 63), with 18 of them treated with NOACS (new oral anticoagulants). AP or AC agents were continued in 96.5% and 80.7% of cases, respectively. Fifty-three patients (6.6%) developed one or more hemorrhagic complications in one eye during this period. In univariate analysis, AC agents were not associated with hemorrhagic complications (P = 0.329) in contrast to AP (P = 0.005). However, in multivariate analysis, AP agents were no longer associated with hemorrhagic complications and the intraoperative use of endodiathermy was the only factor associated with hemorrhagic complications (P = 0.001).

Conclusions

This study showed that AP and AC agents were not a factor associated with hemorrhagic complications during vitreoretinal surgery. The continuation of these treatments should be considered without risk of severe hemorrhagic complications.

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

★ PREMIUM-INHALT
e.Med Interdisziplinär

Für Ihren Erfolg in Klinik und Praxis - Die beste Hilfe in Ihrem Arbeitsalltag als Mediziner

Mit e.Med Interdisziplinär erhalten Sie Zugang zu allen CME-Fortbildungen und Fachzeitschriften auf SpringerMedizin.de.

Alle e.Med Abos bis 30. April 2021 zum halben Preis!

Jetzt e.Med zum Sonderpreis bestellen!

Literatur
Über diesen Artikel

Weitere Artikel der Ausgabe 3/2018

Graefe's Archive for Clinical and Experimental Ophthalmology 3/2018 Zur Ausgabe

Neu im Fachgebiet Augenheilkunde

10.02.2021 | Katarakt | Leitthema | Ausgabe 3/2021

Therapie der postoperativen Endophthalmitis

Operieren oder nur injizieren?

08.02.2021 | Vaskulitiden | Übersichten | Ausgabe 3/2021 Open Access

Intraokulare Entzündungen bei Brolucizumab-Anwendung

Patientenmanagement – Diagnose – Therapie

28.01.2021 | themenschwerpunkt | Ausgabe 1/2021 Open Access

Fünfzig Jahre Schielbehandlung – Ein Erfahrungsbericht aus Klinik und Praxis

26.01.2021 | themenschwerpunkt | Ausgabe 1/2021

MISS (minimalinvasive Schielchirurgie) zur Strabismuskorrektur